The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1529
Prasterone (Intrarosa) for Dyspareunia
The full article is available to subscribers Subscriber Login   

The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.1-3

TREATMENT OF DYSPAREUNIA — VVA is caused by lack of estrogen and is common among postmenopausal women. It can cause irritation, vaginal dryness, and pain with intercourse.4

Over-the-counter, nonhormonal, vaginal moisturizers and lubricants (Replens, K-Y, and others) may provide ... more       Show References Hide References

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Prasterone (Intrarosa) for Dyspareunia
Article code: 1529b
 Electronic, downloadable article - $25